A Panoramic Spectrum of Complex Interplay Between the Immune System and IL-32 During Pathogenesis of Various Systemic Infections and Inflammation

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2015 Jan 29

PMID 25626592

Citations 18

Authors

Babar Khawar

Muddasir Hassan Abbasi

Nadeem Sheikh

Affiliations

Soon will be listed here.

Abstract

Cytokines have always been of great interest due to their vast potential and participation in the progression and pathogenesis of various ailments. Interleukin-32 (IL-32) is a recently identified cytokine, whose gene is located on human chromosome 16 p13.3, with eight exons and six splice variants (IL-32α to IL-32ζ). IL-32α, the most abundant form, is secreted by different types of cells including T cells, natural killer (NK) cells, monocytes, endothelial cells and epithelial cells. It acts as a preferential mediator and effector of abnormal immune responses to multiple inflammatory and auto immune diseases including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), etc. It was found to stimulate the induction of various chemokines, pro-inflammatory cytokines including IL-1β, IL-6, IL-8, TNF-α and macrophage inflammatory protein-2 (MIP-2). Hence, IL-32 mediates the crucial interplay among immune system and body cells during pathogenesis of various insults. The aim of the present effort is to summarize the role, mechanism of pathogenesis and potential therapeutic applications of IL-32 in different systemic infections and diseased conditions.

Citing Articles

Interleukin-32 positive immune and resident cells in kidney samples from lupus patients: a pilot study.

Truglia S, Ciccia F, Mancuso S, Capozzi A, Rizzo A, Spinelli F Front Immunol. 2025; 15():1475073.

PMID: 39835128 PMC: 11743457. DOI: 10.3389/fimmu.2024.1475073.

Psoriatic arthritis subtypes are phenocopied in humanized mice.

Ritchlin C, Rangel-Moreno J, Martino D, Isett B, Paine A, Bhattacharya S JCI Insight. 2024; 9(15).

PMID: 39114979 PMC: 11383598. DOI: 10.1172/jci.insight.178213.

Interleukin-32 as a biomarker in rheumatic diseases: A narrative review.

Kwon O, Park M, Kim Y Front Immunol. 2023; 14:1140373.

PMID: 36875066 PMC: 9974820. DOI: 10.3389/fimmu.2023.1140373.

Natural killer cells in sepsis: Friends or foes?.

Wang F, Cui Y, He D, Gong L, Liang H Front Immunol. 2023; 14:1101918.

PMID: 36776839 PMC: 9909201. DOI: 10.3389/fimmu.2023.1101918.

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy.

Li K, Tandurella J, Gai J, Zhu Q, Lim S, Thomas 2nd D Cancer Cell. 2022; 40(11):1374-1391.e7.

PMID: 36306792 PMC: 9669212. DOI: 10.1016/j.ccell.2022.10.001.

References

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

Saetta M, Turato G, Maestrelli P, Mapp C, Fabbri L . Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163(6):1304-9. DOI: 10.1164/ajrccm.163.6.2009116. View

Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M . Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2001; 163(6):1476-83. DOI: 10.1164/ajrccm.163.6.9908135. View

Maestrelli P, El Messlemani A, De Fina O, Nowicki Y, Saetta M, Mapp C . Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1508-13. DOI: 10.1164/ajrccm.164.8.2011083. View

Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S . Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 165(10):1404-9. DOI: 10.1164/rccm.2107139. View

Richter A, ODonnell R, Powell R, Sanders M, Holgate S, Djukanovic R . Autocrine ligands for the epidermal growth factor receptor mediate interleukin-8 release from bronchial epithelial cells in response to cigarette smoke. Am J Respir Cell Mol Biol. 2002; 27(1):85-90. DOI: 10.1165/ajrcmb.27.1.4789. View

Kyburz D, Rethage J, Seibl R, Lauener R, Gay R, Carson D . Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum. 2003; 48(3):642-50. DOI: 10.1002/art.10848. View

Saetta M, Baraldo S, Turato G, Beghe B, Casoni G, Bellettato C . Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20(1):28-32. View

Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U . Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol. 2004; 172(2):1256-65. DOI: 10.4049/jimmunol.172.2.1256. View

10.

Fantini M, Monteleone G, Macdonald T . New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13(11):1419-23. DOI: 10.1002/ibd.20212. View

11.

Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg J, Sibilia J . BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum. 2007; 56(10):3202-14. DOI: 10.1002/art.22915. View

12.

Navarro-Gonzalez J, Mora-Fernandez C . The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008; 19(3):433-42. DOI: 10.1681/ASN.2007091048. View

13.

Netea M, Lewis E, Azam T, Joosten L, Jaekal J, Bae S . Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci U S A. 2008; 105(9):3515-20. PMC: 2265135. DOI: 10.1073/pnas.0712381105. View

14.

Chung K, Adcock I . Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008; 31(6):1334-56. DOI: 10.1183/09031936.00018908. View

15.

Nold M, Nold-Petry C, Pott G, Zepp J, Saavedra M, Kim S . Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol. 2008; 181(1):557-65. DOI: 10.4049/jimmunol.181.1.557. View

16.

Park M, Song M, Cho M, Moon D, Yoon D, Han S . Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2011; 135(1):63-72. PMC: 3246653. DOI: 10.1111/j.1365-2567.2011.03513.x. View

17.

Glocker E, Grimbacher B . Inflammatory bowel disease: is it a primary immunodeficiency?. Cell Mol Life Sci. 2011; 69(1):41-8. PMC: 11114923. DOI: 10.1007/s00018-011-0837-9. View

18.

Kudo M, Ogawa E, Kinose D, Haruna A, Takahashi T, Tanabe N . Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. Respir Res. 2012; 13:19. PMC: 3361495. DOI: 10.1186/1465-9921-13-19. View

19.

Xu W, Zhang M, Feng C, Yang X, Pan H, Ye D . IL-32 with potential insights into rheumatoid arthritis. Clin Immunol. 2013; 147(2):89-94. DOI: 10.1016/j.clim.2013.02.021. View

20.

Moon Y, Yoon B, Her Y, Oh H, Lee J, Kim K . IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther. 2012; 14(6):R246. PMC: 3674587. DOI: 10.1186/ar4089. View